Skip to main content

Table 1 Various platforms of COVID-19 vaccines, types of vaccines, manufacturers and the phases it approached

From: Various vaccine platforms in the field of COVID-19

Vaccine Platforms Type of vaccines Developers Phases
Inactivated viruses VLA2001 Valneva, National Institute for Health Research, United Kingdom III
TURKOVAC, Erciyes University and the Health Institute Of Turkey (TUSEV) III
CovIral-Varkat Shifa Pharmed Industrial Co II/III
Vero cell, BBIBP-CorV Sinopharm IV
Inactivated (NDV-based) chimeric vaccine with or without the adjuvant CpG 1018 The Government Pharmaceutical Organization (GPO); PATH; Dynavax I/II
Inactivated COVID-19 vaccine KM Biologics Co., Ltd II/III
Live attenuated virus COVI-VAC Codagenix/Serum Institute of India III
MV-014-212 Meissa Vaccines, Inc I
DNA based vaccines COVIGEN University of Sydney, Bionet Co., Ltd Technovalia I
COVID-eVax Takis + Rottapharm Biotech I/II
INO4800 + electropor-ation Inovio Pharmaceuticals + International Vaccine Institute + Advaccine III
AG0301-COVID19 AnGes + Takara Bio + Osaka University II/III
CORVax-12 OncoSec Immunotherapies; Providence Health & Services I
GX-19N Genexine Consortium II/III
GLS-5310 Gene One Life Science, Inc I/II
Protein subunit VAT00008 Sanofi Pasteur + GSK III
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Livzon Pharmaceutical III
Recombinant SARS-CoV-2 vaccine (CHO Cell) Institute of Microbiology, Chinese Academy of Sciences, AnhuiZhifeiLongcom Biopharmaceutical III
CIGB-66 (RBD + aluminium hydroxide) Center for Genetic Engineering and Biotechnology (CIGB) III
RecombinantSars-CoV-2 Spike protein, Aluminumadjuvanted (Nanocovax) Nanogen Pharmaceutical Biotechnology III
EpiVac Corona Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" III
RNA based vaccines mRNA-1273, mRNA-1273.351 Moderna + National Institute of Allergy and Infectious Diseases (NIAID) IV
BNT162b2 (3 LNP-mRNAs), also known as "Comirnaty" Pfizer/BioNTech + Fosun Pharma IV
CVnCoV Vaccine CureVac AG III
ARCT-021 Arcturus Therapeutics II
LNP-nCoVsaRNA Imperial College London I
Chula Cov19 mRNA vaccine Chulalongkorn University I
SARS-CoV-2 mRNA vaccine (ARCoV) Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Abogen Biosciences III
Viral vector (non-replicating) Recombinant novel coronavirus vaccine(Adenovirus type 5 vector) CanSino Biological Inc./Beijing Institute of Biotechnology IV
Sputnik V (Gam-COVID-Vac) Adeno-based (rAd26-S + rAd5-S) Gamaleya Research Institute; Health Ministry of the Russian Federation III
Ad26.COV2.S Janssen Pharmaceutical IV
GRAd-COV2 (Replication defective Simian Adenovirus (GRAd encoding S) ReiThera + Leukocare + Univercells II/III
VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform Vaxart II
MVA-SARS-2-S University of Munich (Ludwig-Maximilians) I
Viral Vectors (Replicating) DelNS1-2019-nCoV-RBD-OPT1 (Intranasalflu- based-RBD) University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy III
rVSV-SARS-CoV-2-S Vaccine Israel Institute for Biological Research II/III
Virus like particle Corona virus- Like Particle COVID-19 (CoVLP) Medicago Inc III
RBD SARS-CoV-2 HBsAg VLP vaccine Serum Institute of India + Accelagen Pty + SpyBiotech I/II
VBI-2902a VBI Vaccines Inc I/II
SARS-CoV-2 VLP Vaccine The Scientific and Technological Research Council of Turkey II
ABNCoV2 capsid virus-like particle (cVLP) ± adjuvant MF59 Radboud University I
  1. The data is taken from the site of WHO vaccines in clinical development https://www.who.int/teams/blueprint/covid-19/covid-19-vaccine-tracker-and-landscape